trending Market Intelligence /marketintelligence/en/news-insights/trending/vnfjBhuijtkRkCc1FLnFuQ2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

ProQR Therapeutics prices $50M ordinary shares offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ProQR Therapeutics prices $50M ordinary shares offering

ProQR Therapeutics NV is offering 9,090,909 ordinary shares at $5.50 each to raise about $50 million gross proceeds.

The Leiden, Netherlands-based biopharmaceutical company granted the underwriters an option to buy up to 1,363,636 additional ordinary shares in the offering.

Completion of the offering is expected to occur Oct. 18, subject to customary closing conditions.

The Dutch company previously said it will use the offering's net proceeds to fund ongoing research and development activities, as well as for working capital and other general corporate purposes.

ProQR Therapeutics is developing RNA medicines intended to treat severe genetic rare diseases. The company's investigational drug sepofarsen was recently granted rare pediatric disease designation by the U.S. Food and Drug Administration for Leber's congenital amaurosis 10, a genetic eye disorder that appears in infancy.

Citigroup Global Markets and Evercore ISI are acting as joint bookrunners for the offering. Meanwhile, Cantor and JMP Securities are lead managers, with Chardan and Kempen acting as co-managers.